Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic: Leukaemia

European Journal of Clinical Pharmacology

Volumn 53, Issue 1, 1997, Pages 71-74

  Jacqz Aigrain, E ^a   Nafa, S ^a   Medard Y ^a   Bessa, E ^a   Lescoeur, B ^a   Vilmer, E ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

6 Mercaptopurine; Acute lymphoblastic leukaemia

Indexed keywords

MERCAPTOPURINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ERYTHROCYTE LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHATIC LEUKEMIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

6-MERCAPTOPURINE; ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; ERYTHROCYTES; HUMANS; INJECTIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1;

EID: 0030981758     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050339     Document Type: Article

References (23)

1. Neglia JP, Robinson LL (1988) Epidemiology of the childhood acute leukemias. Pediatr Clin North Am 35: 675-692
2. Pui CH, Crist WM (1994) Biology and treatment of acute lymphoblastic leukemia. J Pediatr 124: 491-499
3. Sallan SE, Weinstein HJ, Nathan DG (1981) The childhood leukemias. J Pediatr 99: 676-688
4. Niemeyer CM, Gelber RD, Tarbell NJ (1991) Low-dose versus high-dose methothrexate during remission induction in childhood acute lymphoblastic leukemia (protocol 81-01 update). Blood 78: 2514-2519
5. Bleyer WA (1988) Central nervous system leukemia (1988) Pediatr Clin North Am 35: 789-814
6. Lennard L, Lilleyman JS (1989) Variable 6-mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 7: 1816-1823
7. Lennard L (1992) The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 43: 329-339
8. Weinshilboum RM, Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32: 651-662
9. Lennard L, Lilleyman JS, Van Loon JA, Weinshilboum RA (1990) Genetic variation in response to 6MP for childhood acute lymphoblastic leukemia. Lancet 336: 225-229
10. Cavé H, Guidal C, Delfau MH, Broyart A, Lescoeur B, Rahimy C, Fenneteau O, Monplaisir N, d'Auriol L, Elion J, Vilmer E, Grandchamp B (1994) Prospective monitoring and quantitation of residual blast in childhood acute lymphoblastic leukemia by polymerase chain reaction study of d and g T-cell receptor genes. Blood 83: 1892-1902
11. Kato Y, Matsushita T, Yokoyama T, Mohri K (1991) Determination of 6-mercaptopurine in acute lymphoblastic leukemia patients' plasma by high-performance liquid chromatography. Ther Drug Monit 13: 320-325
12. Lennard L (1987) Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatogr 423: 169-178
13. Lilleyman JS, Lennard L (1994) Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia. Lancet 343: 1188-1190
14. Zimm S, Collins JM, Riccardi R, O'Neil D, Narang PK, Chabner B, Poplack D (1983) Variable bioavailability of oral mercaptopurine: is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 308: 1005-1009
15. Koren G, Ferrazini G, Sulh H, Langevin AM, Kapelushnik J, Klein J, Giesbrecht F, Soldin S, Greenberg M (1990) Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Engl J Med 323: 17-21
16. Hayer S, Lafolie P, Bjork O, Petersen C (1989) 6-mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity. Ther Drug Monit 11: 617-622
17. Schouten TJ, Abreu (de) RA, Bruyn (de) CHMM, Van der Kleijn E, Oosterbaan MJM, Schretlen EDAM, Vaan (de) GAM (1984) 6-mercaptopurine: pharmacokinetics in animals and preliminary results in children. Adv Exp Med Biol 165: 367-370
18. Regelson W, Holland JF, Gold GL (1967) 6-mercaptopurine (NCS-755) given intravenously at weekly intervals to patients with advanced cancer. Cancer Chemother Rep 51: 277-282
19. Zimm S, Ettinger LJ, Holcenberg JS, Kamen BA, Vietti TJ, Belasco J, Cogliano-Shutta N, Balis F, Lavi LE, Collins JM, Poplack DG (1985) Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Res 45: 1869-1873
20. Lennard L, Keen MB, Lilleyman JS (1986) Oral 6-mercaptopurine in childhood leukemia: Parent drug pharmacekinetics and active metabolite concentrations. Clin Pharmacol Ther 40: 287-292
21. Tidd DM, Patterson ARP (1974) A biochemical mechanism for the delayed cytotoxic reaction of 6 mercaptopurine. Cancer Res 34: 738-746
22. Bökkerink JPM, Stet EH, Abreu (de) RA, Damea FJM, Hulscher TW, Bakker MAH, Van Baal JA (1993) 6-mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. Biochem Pharmacol 45: 1455-1463
23. Adamson PC, Balis FM, Hawkins ME, Murphy RF, Poplack RF (1993) Desulfuration of 6-mercaptopurine. The basis for the paradoxal cytotoxicity of thiopurines in cultured human leukemic cells. Biochem Pharmacol 46: 1627-1636